3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Polycythemia Vera
10
Brain Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Leukemia, Myeloid, Chronic-Phase
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Leukemia
9
Glioblastoma
9
Leukemia, Myeloid, Acute
8
Meningioma
7
Head and Neck Neoplasms
7
Gliosarcoma
6
Myelodysplastic Syndromes
4
Glioma
4
Central Nervous System Neoplasms
4
Neoplasms
3
Myeloproliferative Disorders
3
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Laryngeal Neoplasms
3
Esophageal Neoplasms
3
Treatment-Refractory Solid Tumors
2
Thrombocythemia, Essential
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Pharyngeal Neoplasms
2
Paranasal Sinus Neoplasms
2
Oropharyngeal Neoplasms
2
Myelodysplastic-Myeloproliferative Diseases
2
Hypopharyngeal Neoplasms
2
Congenital Abnormalities
2
Interventions
Cyclophosphamide
409
Methotrexate
246
Cytarabine
231
Vincristine
188
fludarabine phosphate
172
Dexamethasone
169
fludarabine
143
Etoposide
143
Peripheral Blood Stem Cell Transplantation
136
Filgrastim
132
Whole-Body Irradiation
116
Mycophenolic Acid
115
Busulfan
112
Doxorubicin
109
Tacrolimus
106
Mercaptopurine
106
Cyclosporine
95
Radiotherapy
93
Melphalan
93
Rituximab
90
pegaspargase
88
Prednisone
85
Asparaginase
84
Daunorubicin
82
Granulocyte Colony-Stimulating Factor
74
blinatumomab
72
Antilymphocyte Serum
71
Calcium Dobesilate
69
Clofarabine
58
Thiotepa
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Hydroxyurea
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts